Y Intercept Hong Kong Ltd Trims Position in Dyne Therapeutics, Inc. $DYN

Y Intercept Hong Kong Ltd decreased its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 81.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 65,158 shares of the company’s stock after selling 278,568 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Dyne Therapeutics were worth $1,181,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in DYN. Creative Planning increased its position in Dyne Therapeutics by 6.8% in the 3rd quarter. Creative Planning now owns 15,527 shares of the company’s stock valued at $196,000 after acquiring an additional 986 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Dyne Therapeutics by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock valued at $136,000 after purchasing an additional 1,440 shares during the last quarter. Hilton Head Capital Partners LLC purchased a new position in shares of Dyne Therapeutics in the 1st quarter valued at approximately $26,000. Caxton Associates LLP increased its holdings in shares of Dyne Therapeutics by 10.9% in the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock valued at $158,000 after purchasing an additional 1,627 shares during the period. Finally, Steward Partners Investment Advisory LLC raised its stake in shares of Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after purchasing an additional 2,465 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Price Performance

Shares of Dyne Therapeutics stock traded down $0.85 on Friday, hitting $23.42. The company’s stock had a trading volume of 1,514,766 shares, compared to its average volume of 2,236,732. Dyne Therapeutics, Inc. has a 52-week low of $8.24 and a 52-week high of $25.00. The company has a quick ratio of 19.92, a current ratio of 19.92 and a debt-to-equity ratio of 0.17. The firm has a fifty day moving average price of $19.24 and a 200-day moving average price of $18.35. The company has a market capitalization of $3.87 billion, a P/E ratio of -7.27 and a beta of 1.06.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same quarter in the previous year, the company earned ($1.05) EPS. On average, equities research analysts expect that Dyne Therapeutics, Inc. will post -3.02 earnings per share for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In related news, Director Jason P. Rhodes sold 480,240 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $22.79, for a total value of $10,944,669.60. Following the sale, the director owned 875,912 shares of the company’s stock, valued at approximately $19,962,034.48. This represents a 35.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have purchased 9,000 shares of company stock worth $156,800 and have sold 3,111,730 shares worth $64,079,704. 9.46% of the stock is currently owned by company insiders.

Analyst Ratings Changes

DYN has been the topic of several recent research reports. Sanford C. Bernstein boosted their price objective on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Wall Street Zen upgraded shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, July 6th. Evercore set a $33.00 price objective on Dyne Therapeutics in a report on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Finally, TD Cowen began coverage on shares of Dyne Therapeutics in a research note on Friday, June 26th. They set a “buy” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.17.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.